Changes in the Cause of Death Among HIV Positive Subjects Across Europe: Results from the EuroSIDA Study
Overview
Authors
Affiliations
Objectives: The causes of death among HIV-positive patients may have changed since the introduction of highly active antiretroviral therapy (HAART). We investigated these changes, patients who died without an AIDS diagnosis and factors relating to pre-AIDS deaths.
Methods: Analyses of 1826 deaths among EuroSIDA patients, an observational study of 8556 patients. Incidence rates of pre-AIDS deaths were compared to overall rates. Factors relating to pre-AIDS deaths were identified using Cox regression.
Results: Death rates declined from 15.6 to 2.7 per 100 person-years of follow-up (PYFU) between 1994 and 2001. Pre-AIDS incidence declined from 2.4 to 1.1 per 100 PYFU. The ratio of overall to pre-AIDS deaths peaked in 1996 at 8.4 and dropped to < 3 after 1998. The adjusted odds of dying following one AIDS defining event (ADE) increased yearly (odds ratio, 1.53; P < 0.001), conversely the odds of dying following three or more ADE decreased yearly (odds ratio, 0.79; P < 0.001). The proportion of deaths that followed an HIV-related disease decreased by 23% annually; in contrast there was a 32% yearly increase in the proportion of deaths due to known causes other than HIV-related or suicides. Injecting drug users (IDU) were significantly more likely to die before an ADE than homosexuals (relative hazard, 2.97; P < 0.0001) and patients from northern/eastern Europe (relative hazard, 2.01; P < 0.0001) were more likely to die pre-AIDS than southern patients.
Conclusions: The proportion of pre-AIDS deaths increased from 1994 to 2001; however, the incidence of pre-AIDS deaths and deaths overall declined. IDU and subjects from northern/eastern Europe had an increased risk of pre-AIDS death. HIV-positive patients live longer therefore it is essential to continue to monitor all causes of mortality to identify changes.
Clinico-demographic and survival profile of people living with HIV on antiretroviral treatment.
Shaik R, Holyachi S, Ahmad M, Miraj M, Alzahrani M, Ahmad R Front Public Health. 2023; 11:1084210.
PMID: 37064669 PMC: 10098347. DOI: 10.3389/fpubh.2023.1084210.
Prevalence and risk factors of high cholesterol and triglycerides among people with HIV in Texas.
Buendia J, Sears S, Mgbere O AIDS Res Ther. 2022; 19(1):43.
PMID: 36123679 PMC: 9484232. DOI: 10.1186/s12981-022-00467-y.
Hwang H, Yu H, Kang K, Kim W, Park S, Ku J Korean J Transplant. 2022; 33(3):60-64.
PMID: 35769407 PMC: 9186908. DOI: 10.4285/jkstn.2019.33.3.60.
Arora S, Mahesh A, Mahesh N, Verma N Indian J Sex Transm Dis AIDS. 2021; 42(2):118-124.
PMID: 34909615 PMC: 8628102. DOI: 10.4103/ijstd.IJSTD_28_19.
Al Bitar S, Ballouz T, Doughan S, Gali-Muhtasib H, Rizk N World J Gastrointest Pathophysiol. 2021; 12(4):59-83.
PMID: 34354849 PMC: 8316837. DOI: 10.4291/wjgp.v12.i4.59.